RedHill Biopharma Commences $11 Million Enforcement Action Against Kukbo

RedHill Biopharma's Legal Action against Kukbo Co. Ltd

RedHill Biopharma Ltd. (Nasdaq: RDHL), a prominent biopharmaceutical firm, has recently initiated legal proceedings to enforce a significant judgment rendered by the New York Supreme Court against Kukbo Co. Ltd. The company aims to collect approximately $10.9 million following a definitive court ruling. This amount reflects the main award, legal fees, and accrued interest.

The New York Supreme Court's judgment was established in November 2025, concluding RedHill’s legal dispute with Kukbo over financial matters related to their business dealings. RedHill's claim was further bolstered as Kukbo missed the chance to appeal by failing to meet the deadline earlier this year. Consequently, no further appeals can be made, cementing RedHill’s legal victory.

In the judgment, the court awarded RedHill around $8.9 million as the principal sum along with an additional $1.95 million to cover legal costs and expenses incurred during the court proceedings. This total includes statutory interest set at 9%, which continues to accrue while enforcement actions are underway.

To safeguard its interests, RedHill had earlier secured a preliminary court order in Korea that prohibits Kukbo from disposing of its assets. This preemptive measure is strategic, ensuring that as RedHill pursues enforcement, Kukbo cannot evade payment by transferring or liquidating its assets.

Upon commencing enforcement proceedings in Korea, RedHill has served the necessary legal documents to Kukbo. The company is now waiting for Kukbo’s formal response as well as further instructions from the Korean court regarding the scheduling of hearings pertinent to this matter.

While RedHill remains hopeful about recovering the amounts awarded by the New York court, no guarantees can be provided concerning the timing or total sums that may ultimately be recovered.

About RedHill Biopharma

RedHill Biopharma specializes in the development and commercialization of therapeutics aimed at treating gastrointestinal diseases, infectious diseases, and cancers. The company’s portfolio includes its FDA-approved gastrointestinal drug, Talicia®, which is used for treating Helicobacter pylori infection in adults. RedHill conducts its development efforts primarily in the U.S. and has established a co-commercialization partnership with Cumberland Pharmaceuticals to enhance its market reach.

Apart from Talicia®, RedHill is advancing several clinical-stage programs. These include opaganib (ABC294640), an innovative oral drug that targets multiple medical conditions, including oncology and various infectious diseases. Additionally, the firm is working on RHB-102 (Bekinda®), aimed at addressing gastrointestinal intolerance associated with certain medications.

As RedHill navigates through legal challenges, it exemplifies resilience in asserting its rights and commitments while simultaneously advancing its developmental pipeline to strengthen its position in the biopharmaceutical sector.

To learn more about RedHill and its mission to deliver effective therapeutics, visit their official website or follow their updates online.